| Post date: 2020/09/1 |
Medscape Clinical Trend: Metformin⠀
⠀
The most commonly prescribed drug for #type2 #diabetes may be associated with reduced risk for death due to COVID-19. ⠀
⠀
The latest results, which are not yet peer reviewed, were recently published online and show a significant reduction in mortality in patients with diabetes and COVID-19 who used #metformin. ⠀
⠀
These findings support the results of four previous studies that also showed a reduction in mortality among metformin users compared with nonusers. ⠀
⠀
However, experts say that the randomized controlled trials needed to conclusively prove this benefit are "almost impossible in the context of COVID-19."⠀
⠀
Metformin has been in the news this week for other reasons as well. Tap the link in our bio to read further study analysis.
⠀
The most commonly prescribed drug for #type2 #diabetes may be associated with reduced risk for death due to COVID-19. ⠀
⠀
The latest results, which are not yet peer reviewed, were recently published online and show a significant reduction in mortality in patients with diabetes and COVID-19 who used #metformin. ⠀
⠀
These findings support the results of four previous studies that also showed a reduction in mortality among metformin users compared with nonusers. ⠀
⠀
However, experts say that the randomized controlled trials needed to conclusively prove this benefit are "almost impossible in the context of COVID-19."⠀
⠀
Metformin has been in the news this week for other reasons as well. Tap the link in our bio to read further study analysis.
Keywords: coronavirus | covid19 |
View: 481 Time(s) |
Print: 176 Time(s) |
Email: 0 Time(s) |
0 Comment(s)
